Top Story

FDA grants orphan drug status to SL-701 for glioma treatment

January 30, 2015

The FDA today granted orphan drug designation to SL-701 for the treatment of glioma, according to a press release from the drug’s manufacturer.

SL-701 (Stemline Therapeutics) is an enhanced immunotherapy that activates the immune system to kill malignant gliomas.

Mary Ann Burg, PhD, LCSW In the JournalsPerspective

Cancer survivors' needs 'not sufficiently addressed' by medical community

January 30, 2015
Physical, financial, emotional and mental health problems persist as unmet needs in cancer survivors, according to study results. Mary Ann Burg, PhD, LCSW, professor…
In the Journals

Molecular subtypes of stage III colon cancer linked to different patient outcomes

January 30, 2015
Researchers have identified subtypes of stage III colon cancer based on molecular markers associated with differences in clinical and pathological features as well as…
Lecia V. Sequist, MD, MPH In the Journals

First-line afatinib extended OS in exon 19 deletion-positive lung adenocarcinoma

January 30, 2015
Patients with lung adenocarcinoma who harbored exon 19 deletion EGFR mutations experienced significantly longer OS when treated with first-line afatinib instead of…
More News Headlines »
Health Care Legislative and Regulatory Update Perspective
Arnold Porter

Persistent technical issues heighten concern over Sunshine’s data accuracy

Spine Surgery Today, November/December 2014
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »